Senate Democrats release deal on drug price negotiations, Part D and Medicare Advantage cap AstraZeneca, GSK and more weathered Q2's economic headwinds, but Roche's stock took a hit: analysts BeiGene's R&D chief knows PD-1 is crowded. But TIGIT, combos and a Novartis partnership put asset in play Sponsored: Decentralized clinical trials, patient experience and the role of supply chain management Labcorp launches monkeypox PCR tests through CDC initiative Pfizer gets access to Touchlight's 'doggybone DNA' tech to make vaccines, gene therapies and more Applied Molecular Transport’s UC drug hits roadblock after proving less effective than Humira Watson Health, under new investment firm ownership, is reborn as Merative Joining the resistance: Boehringer rounds up allies to build €40M anti-superbug startup Fairtility welcomes EU approval for embryo assessment AI Roche's Lunsumio eyes year-end FDA verdict to be first bispecific for non-Hodgkin lymphoma OBI Pharma culls early cancer asset as it focuses on later-stage bets Guardant Health takes its cancer blood tests to China through clinical trial partnership Report: These are the factors impacting individual, small group premiums in 2023 Pfizer acquisition target ResApp reels in FDA nod for iPhone app to detect sleep apnea Featured Story | By Robert King Senate Democrats released a deal Wednesday aimed at giving Medicare the power to negotiate for lower drug prices and include inflationary caps on Medicare drug costs. read more |
| |
|---|
|
Top Stories By Kevin Dunleavy A set of economic headwinds, including the Ukraine War, COVID lockdowns in China, inflation, supply chain problems and the resulting rise in operational costs has led some companies to reconsider their projections for this year. With second quarter earnings reports due in the coming weeks, AstraZeneca and GSK appear to have survived the headwinds more successfully than most, according to a European Big Pharma report from ODDO BHF. But not so much for Roche. read more By Angus Liu With an FDA target decision date set for next week, BeiGene and Novartis’ tislelizumab has a real chance of becoming the first China-developed PD-1 cancer immunotherapy to reach the U.S. And BeiGene is already lining up potential combination approaches, including TIGIT. read more Sponsored By: Parexel The rise of clinical trial complexity has been well-documented but the impact on logistics is not well understood. Here, we look at decentralized trials, patient experience and the role of logistics. read more By Andrea Park Labcorp was tapped by the U.S. Centers for Disease Control and Prevention last month to help make monkeypox testing widely available through its broad network of diagnostic labs. read more By Zoey Becker Pfizer will be able to use Touchlight's "doggybone DNA" technology to produce mRNA vaccines and more thanks to a new licensing agreement. read more By James Waldron Applied Molecular Transport’s stock crashed down to earth this morning as the biotech’s inflammatory bowel disease drug failed to beat Humira in a phase 2 trial in ulcerative colitis. read more By Dave Muoio Francisco Partners celebrated the close of its Watson Health transaction by relaunching IBM's ill-fated analytics business under a new name. read more By Nick Paul Taylor Boehringer Ingelheim is pumping 30 million euros ($31 million) into the fight against drug-resistant bacteria. Working with Evotec and bioMérieux, the German drugmaker has set up Aurobac Therapeutics, a biotech that will take a precision medicine approach to diagnosing and treating infections. read more By Andrea Park The EU's new medical device regulation standards have given birth to a commercially available artificial intelligence tool that could potentially boost the success rate for in vitro fertilization procedures. read more By Angus Liu Roche’s Lunsumio could soon become the first bispecific to join the U.S. treatment armamentarium for non-Hodgkin lymphoma, thanks to an FDA priority review that puts it on a collision course with CAR-T therapies. read more By James Waldron OBI Pharma is dropping its cancer antibody over cost concerns after a glimpsing preliminary phase 1/ 2 data and will focus on its late-stage oncology programs. read more By Conor Hale With the Hangzhou-based clinical lab company Adicon, Guardant will offer its blood and tissue analysis portfolio to biopharma companies. read more By Paige Minemyer The lingering effects of COVID-19, the end of enhanced subsidies for exchange plans and global inflation are among the key trends impacting premiums in 2023, according to a new report. read more By Andrea Park While ResApp Health waits for a final decision on Pfizer’s acquisition proposal, the Australian tech developer isn’t just sitting around. read more |
| On Demand Webinar: Automating Cell Therapy Product Now Available on Demand The major key cost drivers of the autologous CAR T-cell therapy are generally QC analytics and biocharacterization of viral vector and supporting starting biomaterials, all of which could be developed and managed in-house. The cost and impacts revealed through the decision-making process emphasize the need for automation. Watch now to learn more. |
|---|
Resources Sponsored by: Catalent Pharmaceutical drug developers continue to realize the strong therapeutic potential of highly potent active pharmaceutical ingredients (HPAPIs). This is particularly true for therapeutic areas such as oncology, where highly potent drugs are becoming more commonplace. Sponsored by: Cognizant Explore how Cognizant SIP helped Roche streamline its global feasibility process. Sponsored by: Catalent Pharmaceutical development companies face several challenges when developing orally bioavailable formulations of active pharmaceutical ingredients. Up to 70% of new drug molecules are poorly soluble in gastrointestinal fluids and can exhibit poor absorption across the gut wall. Sponsored by: Blue Matter Consulting For an emerging biopharma company, Europe can be very attractive. But it can also be complex and confusing. This e-book covers the 12 most common pitfalls for companies entering European markets for the first time, offering guidance to help growing companies avoid them and succeed. Sponsored by: CG Life Explore the new cell therapy handbook from Thermo Fisher Scientific. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Thermo Fisher Scientific Sponsored by Thermo Fisher Scientific The journey for starting or expanding a lab can be exhilarating, while also being challenging--learn how this free program provides savings and solutions to support your goals. Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? | 